A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/165
A61K 9/20 (2006.01) A61J 3/10 (2006.01)
Patent
CA 1158555
Abstract of the Disclosure A divisible tablet having controlled and delayed release of the active substance, characterised in that it consists of a compact, with or without a coating having no influence on the release of said active substance, said compact being formed by pressing a granulate of at least one active sub- stance and an adjunct composition which effects the controlled and delayed release of the active substance to form a granulate-retard matrix, with or without one or more additional granulate adjunct compositions which contain an active substance or do not contain such active substance and are arranged in longitudinal layers, the compact being of an oblong shape in which the ratio of length to width to depth is approximately 2.5 to 5:approximately 0.9 to 2:1 and the width constitutes at most 2/3 of the length, and in which one or more deep dividing grooves are present which run perpendicularly to the length and depth and have a total depth of from approximately 1/3 to approxi- mately 1/2 of the depth of the tablet, but are at least so deep that one frac- ture surface area multiplied by the number of possible fragments constitutes a maximum of 15% of the surface area of the undivided tablet, the base and top faces independently of one another are planar or are convexly curved about the longitudinal axis or about parallels to this axis, the side faces are planar, the end faces can be of any shape and with or without bevelled or rounded edges.
358243
Hess Hans
Voellmy Carlo
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Divisible tablet having controlled and delayed release of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Divisible tablet having controlled and delayed release of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Divisible tablet having controlled and delayed release of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-907017